NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
IRA Negotiated
ZITUVIMET (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2023.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET is a fixed-dose combination tablet containing sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride for oral treatment of type 2 diabetes mellitus. It works by inhibiting dipeptidyl peptidase-4 enzyme, prolonging incretin hormone activity to improve glycemic control. This combination leverages two complementary mechanisms to enhance blood glucose management in patients inadequately controlled on monotherapy.
Growth
Early-stage growth product with significant pricing pressure from IRA negotiations, suggesting moderate commercial team expansion potential with focus on volume and access strategies.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
ZITUVIMET represents a growth-stage generic-eligible product with zero currently linked job openings, reflecting a smaller commercial footprint typical of Aurobindo's market positioning. Working on this product offers exposure to managed care negotiations, pricing strategy, and market access in a highly competitive therapeutic class.
Worked on ZITUVIMET at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.